Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Enzyme replacement therapy in three patients with MPS II (CROSBI ID 549094)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Petković, Giorgie ; Barišić, Ingeborg Enzyme replacement therapy in three patients with MPS II // Paediatria Croatica. Supplement / Barišić, Ingeborg (ur.). 2009. str. 48-48

Podaci o odgovornosti

Petković, Giorgie ; Barišić, Ingeborg

engleski

Enzyme replacement therapy in three patients with MPS II

Mucopolysaccharidosis type II (MPS II) is a rare lysosomal storage disorder due to the deficiency of the lysosome enzyme iduronate sulfatase (IDS). The enzymatic defect leads to the accumulation of dermatan and heparan sulfate in lysosomes causing progressive dysfunction of many tissues and organs. Enzyme replacement therapy (ERT) is now available with idursulfase. Aim: to present our experience with ERT treatment in three patients with MPS II. Patients/Methods: The diagnosis of MPS II was made based on clinical criteria, abnormal urinary glycosaminoglycan (GAG) excretion, deficient serum and/or fibroblast IDS activity, and molecular testing. Two patients had severe form of disease and one patient was mildly affected. After one year of therapy with idursulfase (ElapraseŸ) in two patients with advanced form of MPS II we found no progression of the disease, with stationary findings in stamina, cardiologic status and liver size. Urinary GAG levels returned to nearly normal levels. One of the two patients, who has epilepsy, showed a marked decrease in the frequency of seizure attacks. The patient with a mild form of MPS II, showed after 6 months of treatment increase in stamina, pulmonary function tests, range of motion, and decrease in liver size. Conclusion: ERT treatment prevented the progression of the disorder in two patients with advanced form of disease and considerably improved the condition of the mildly affected patient. The therapy was well tolerated and without serious side effects.

MPS II

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

48-48.

2009.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Paediatria Croatica. Supplement

Barišić, Ingeborg

Zagreb:

1330-724X

Podaci o skupu

8th Balkan Meeting on Human Genetics

poster

15.05.2009-17.05.2009

Cavtat, Hrvatska

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost